Early Study Shows Promising Results for New Oral Heart Failure Drug AC01

A Phase 1b/2a study on AnaCardio's novel oral drug AC01 for heart failure with reduced ejection fraction (HFrEF) has yielded positive findings, published in The Lancet. The research indicates that AC01, a first-in-class treatment, exhibits a favorable safety and tolerability profile. Furthermore, it demonstrated rapid and sustained improvements in key cardiac functions, suggesting potential for future heart failure treatment.